Skip to main content
. Author manuscript; available in PMC: 2022 Oct 28.
Published in final edited form as: J Antimicrob Chemother. 2022 Aug 29;77(11):3110–3117. doi: 10.1093/jac/dkac290

Table 1.

Baseline characteristics of participants included in the primary analysis (assessment of associations between the outcome variables and dolutegravir AUC0-24 estimates) and secondary analysis (assessment of associations between the outcome variables and polymorphisms for UGT1A1 rs887829 C→T and SLC22A2 rs316019 C→A).

Baseline characteristics Primary analysis
(n=464)		 Secondary analysis
(n=301)
Age, years (median, IQR) 32 (27 – 38) 32 (27 – 38)
Sex    
    Female, % 58.6 61.5
    Male, % 41.4 38.5
Race    
    Black, % 100 99.7
    Mixed, % 0 0.3
CD4 count, cells/mm3 (median, IQR) 282 (165 – 442) 292 (161 – 457)
HIV-1 RNA log10, copies/mL (median, IQR) 4.4 (3.8 – 4.9) 4.4 (3.8 – 4.9)
TAF/TDF arm    
    TAF, % 49.8 51.2
    TFD, % 50.2 48.8
MMS score, (median, IQR) 0 (0 – 1) 0 (0 – 1)
Sleep quality, (median, IQR) 9 (8 – 10) 9 (8 – 10)

IQR=interquartile range, RNA= ribonucleic acid, TAF = tenofovir alafenamide, TDF = tenofovir disoproxil fumarate, MMS = modified mini screen